Wegovy Rash: How Common, How Long It Lasts, What Helps
Yes. In the Wegovy trials, 3% of people on 2.4 mg had rash, against 0% on placebo: a little above placebo.
- In the Wegovy label
- Yes, with a rate
- On Wegovy 2.4 mg
- 3%
- On placebo
- 0%
Wegovy overview
After five half-lives (35 d), about 3% is left. The half-life is about 1 week, with half gone after 7 d.
STEP 1 covered 68 weeks: 14.9% of body weight, compared with 2.4% on placebo.
Prices by month in US dollars include the list price and self-pay offers, all read from the maker's price page.
Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.
Against placebo, how often is it seen on Wegovy?
Wegovy rash appears by dose group in the label trials. The placebo group is the comparison group from the same trial.
| Medicine and dose | Rash | Placebo | More than placebo | People in the trials |
|---|---|---|---|---|
| Wegovy 2.4 mg | 3% | 0% | +3 points | Children 12 and older with obesity |
| Wegovy 2.4 mg | 3% | 0% | +3 points | Children with obesity who are 12 or older (label term: urticaria) |
Source: the Wegovy label (DailyMed).
Wegovy rash compared with other GLP-1s
Every label covers its own trials, which included different groups of people. Treat it as a rough guide.
| Medicine | Highest rate in the label | Dose group | Placebo | People in the trials |
|---|---|---|---|---|
 Saxenda | 3.2% | all doses | 0% | Children 12 and older with obesity |
| Wegovy | 3% | 2.4 mg | 0% | Children 12 and older with obesity |
 Ozempic | Listed, no rate given | – | – | – |
 Mounjaro | Listed, no rate given | – | – | – |
 Zepbound | Listed, no rate given | – | – | – |
 Trulicity | Listed, no rate given | – | – | – |
 Victoza | Listed, no rate given | – | – | – |
| Byetta | Listed, no rate given | – | – | – |
 Rybelsus | Not listed | – | – | – |
 Foundayo | Not listed | – | – | – |
Reference: Wegovy label (DailyMed) and Saxenda label (DailyMed).
Source: FDA label, DailyMed.
What the Wegovy label says
Word for word, the label mentions rash here:
“In a pediatric clinical trial for weight reduction, rash was reported in 3% of WEGOVY-treated patients and 0% of placebo-treated patients, and urticaria was reported”
Source: FDA label, DailyMed.